2713 results about "Nicotinamide" patented technology

The invention provides a plant nutrient solution for soilless culture of tomato. The plant nutrient solution is prepared by the following raw materials in part by weight: 2 to 4 parts of potassium nitrate, 3 to 8 parts of calcium nitrate, 1 to 5 parts of magnesium sulfate, 1 to 3 parts of potassium phosphate, 1 to 2 parts of potassium sulphate, 1 to 2 parts of monopotassium phosphate, 0.1 to 0.15 part of Na2-EDTA, 0.05 to 0.1 part of Fe-EDTA, 0.01 to 0.05 part of molybdic acid, 0.01 to 0.03 part of manganese sulfate, 0.3 to 0.5 part of sodium tetraborate, 2 to 4 parts of superphosphate, 0.003 to 0.01 part of zinc sulfate, 0.001 to 0.002 part of copper sulfate, 0.001 to 0.003 part of ammonium nitrate, 1 to 3 parts of urea, 1 to 2 parts of organic acid, 0.5 to 1 part of beta cyclodextrin, 0.05 to 0.1 part of vitamin B, 2 to 4 parts of chitosan, 1 to 2 parts of nicotinamide, 0.5 to 2 parts of amino acid, 0.3 to 0.5 part of diethyl aminoethyl hexanoate, 0.02 to 0.5 part of gibberellin, and 5,000 to 7,000 parts of water. According to experiment, the plant nutrient solution provided by the invention can be used for carrying out soilless culture of tomato, and the tomato has high plant height, thick stem, high cluster and high output.

The invention provides methods and compositions for modulating the life span of eukaryotic and prokaryotic cells and for protecting cells against certain stresses, e.g., heatshock. One method comprises modulating the flux of the NAD+ salvage pathway in the cell, e.g., by modulating the level or activity of one or more proteins selected from the group consisting of NPT1, PNC1, NMA1 and NMA2. Another method comprises modulating the level of nicotinamide in the cell.

The present invention provides compositions and methods for use in the treatment of hyperproliferative dermal diseases. Specifically, the present invention teaches pharmaceutical compositions for topical administration where the compositions contain nicotinamide and a vitamin D metabolite, calcipotriol, which are particularly effective in treating and in the maintenance treatment of psoriasis and other related dermal disorders and diseases.

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: where q is 1, 2, or 3, W3 is -O-; -N(R9)-; or -OC(=O)-; R7 is selected from -H; -(C1-C6) alkyl, -(C2-C6) alkenyl, or -(C2-C6) alkynyl substituted by 0 to 3 substituents R10; -(CH2)u-(C3-C7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R10; and phenyl or benzyl substituted by 0 to 3 R14; R8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is -O-; -S(=O)t-, where t is 0, 1, or 2; or -N(R3)-; Y is =C(R1a)-, or -[N<custom-character file="US20020111495A1-20020815-P00900.TIF" wi="20" he="20" id="custom-character-00001"/>(O)k] where k is 0 or 1; R4, R5 and R6 are (1) -H; provided that R5 and R6 are not both -H at the same time, -F; -Cl; -(C2-C4) alkynyl; -R16; -OR16; -S(=O)pR16; -C(=O)R16, -C(=O)OR16, -C(=O)OR<highlight><sup

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I):

where m, n, p, V, R1, R2, R3, R4, R5 and R6 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

The invention discloses an external skin care product capable of adjusting skin immunity and delaying skin aging. The external skin care product is characterized by comprising powder, an aqueous solution and emulsion, wherein the powder comprises oligopeptide-1 and ginsenoside; the aqueous solution comprises glycyrrhiza glabra root extract, artemisia capillaris flower extract, mulberry root extract, jujube fruit extract, scutellaria root extract, hydrolyzed rice protein and nicotinamide; and the emulsion comprises hgytantriol bifida ferment lysate, creatine, carnosine, alpha glucosyl hesperidin, hexapeptide-3, centella asiatica extract, coenzyme Q10 inclusion complex, opuntia ficus-indica stem extract, rhodiola rosea extract, saussurea involucrate extract, pseudo-ginseng root extract and Chinese angelica extract inclusion complex. According to the external skin care product, the powder, the aqueous solution and the emulsion are jointly used, and the external skin care product can reduce wrinkle and pachulosis, even skin tone and improve skin elasticity and skin firmness, so that the skin is finer and smoother and looks young.

The invention discloses functional fatty powder and a preparation method thereof, and belongs to the technical field of feeds. The functional fatty powder is characterized in that raw materials comprise the following components in parts by weight: 30-50 parts of concentrated omega-fatty acid fat, 10-20 parts of lecithin, 8-15 parts of concentrated linolenic acid fat, 8-15 parts of MCT, 1-5 parts of choline, 1.5-5.5 parts of nicotinamide, 1-5 parts of a composite emulsifying agent, 3-8 parts of a composite antioxidant, 2-8 parts of vitamin C, and 40-70 parts of encrusting substances or 30-60 parts of carriers. The functional fatty powder provided by the invention is small in addition quantity, high in cost performance ratio, good in stability, high in nutrient value and high in fat utilization rate; the functional fatty powder not only can greatly improve the growing property and the reproductive property of animals but also can improve the immunity of the animals and promote the development of animal organisms, so that the functional fatty powder is an excellent feed additive.

The invention discloses a recombinant microorganism for preparing dharma diene and protopanoxadiol and a construction method of the recombinant microorganism. The construction method of the recombinant bacteria comprises a step of adding dharma diene synthase, protopanoxadiol synthase and nicotinamide adenine dinucleotide phosphate - cytochrome P450 reductase encoding gene into saccharomyces cerevisiae to obtain recombinant bacteria I. According to the recombinant microorganism for preparing the dharma diene and the protopanoxadiol and the construction method of the recombinant microorganism, by means of homologous recombination, the dharma diene synthase, the protopanoxadiol synthase and the nicotinamide adenine dinucleotide phosphate - the cytochrome P450 reductase encoding gene are all added into the saccharomyces cerevisiae to obtain the initial recombinant bacteria, and the effect that the initial recombinant bacteria can produce trace amount of the dharma diene and trace amount of the protopanoxadiol is discovered; tHMG1 activity of the initial recombinant bacteria is further improved, and therefore intermediate recombinant bacteria are obtained, and by means of the intermediate recombinant bacteria, the yield of the dharma diene and the yield of the protopanoxadiol are significantly increased; the activity of one or two or three of ERG1, ERG9 and ERG20 are improved on the basis of the intermediate recombinant bacteria, and the effect that the recombinant bacteria which can be used to increase the yield of the dharma diene and the yield of the protopanoxadiol are constructed is also discovered. By means of the recombinant microorganism for preparing the dharma diene and the protopanoxadiol and the construction method of the recombinant microorganism, the foundation is laid for artificially synthesizing the dammar diene and the protopanoxadiol.

The invention relates to a method for measuring alkaloid in tobacco and tobacco products, which is characterized by dissociating alkaloid from the tobacco and tobacco products by using sodium hydroxide solution, extracting the alkaloid from samples by using triethylamine/trichloromethane solution, and detecting content of five kinds of alkaloid with GC-MS ( Gas Chromatograph-Mass Spectrum) quantitative analysis. Compared with other methods for analyzing the alkaloid, the invention has the advantages that alkaloid is separated from the tobacco by DB-35MS chromatographic columns so as to separate nornicotine and myosmine in the tobacco and accurately quantify target matters; batch sampling is carried out on the separation of nicotinamide and other alkaloid so as to detect the nicotinamide with high content in the tobacco and meet the quantitative analysis of other alkaloid with low content; the standard working curves of standard matters are separately compounded so as to avoid influence on quantization of other alkaloid by alkaloid catabolite existing in the standard samples. The method is simple and convenient and has the advantages of good repeatability, high analyzing and measuring sensitivity, and accurate quantization.

The present invention provides a method of treating a mammal having a neuropathophysiological condition, comprising the step of administering to the mammal in need of such treatment a compound selected from nicotinamide or salts or prodrugs thereof, nicotinamide mononucleotide or salts or prodrugs thereof, nicotinamide adenine dinucleotide or salts or prodrugs thereof, nicotinamide riboside nicotinamide or salts or prodrugs thereof, phosphoribosyltransferase, or combinations thereof. Further provided is a method for treating a mammal having a neuropathophysiological condition or suspected to develop said neuropathophysiological condition, comprising the step of administering to said mammal an inhibitor of CD38 NAD⁺ glycohydrolase activity.

Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.

The invention discloses a novel method for preparing beta-nicotinamide mononucleotide (beta-NMN). According to the method, D-5-ribose phosphate, ATP and nicotinamide are used as raw materials, beta-nicotinamide mononucleotide can be efficiently and biologically synthesized by catalysis of immobilized whole-cell containing phosphoribosylpyrophosphate synthetase and nicotinamide phosphoribosyltransferase, and the concentration of the synthesized beta-nicotinamide mononucleotide can be 13.3g/L, so that the synthetic amount and conversion rate of beta-NMN enzymatic reaction can be increased, the immobilized whole-cell can be used repeatedly, and the reaction complexity and production cost can be reduced.

The invention discloses a recombinant human NADH (nicotinamide-adenine dinucleotid) dehydrogenase subunit-4 gene and a constructing method of an expression vector thereof. The nucleotide sequence of the gene is shown in SEQ ID NO:1, and the size of the nucleotide sequence is 2889 bp. The constructing steps of adeno-associate virus vectors are as follows: firstly constructing a recombinant adeno-associated virus vector containing the human NADH dehydrogenase subunit-4 gene, and then coating, infecting, purifying, concentrating and identifying the recombinant adeno-associated virus. According to the method, the recombinant adeno-associated virus vector with the recombinant human NADH dehydrogenase subunit-4 gene can be quickly and simply constructed, and is packaged to obtain the adeno-associated virus vector with complex defects. The gene can be used for gene therapy of LHON (leber's hereditary optic neuropathy).

A method of stabilizing R-α-lipoic acid includes combining R-α-lipoic acid with nicotinamide in a weight ratio between about 10:4 to about 10:8. A composition for treating oxidative stress includes R-α-lipoic acid and nicotinamide in a weight ratio of between about 10:4 and about 10:8.

The invention discloses a preparation method of a nicotinamide fungicide namely boscalid. The preparation method comprises the following steps: starting from a raw material namely para chlorobromobenzene, performing Grignard reaction, and synthesizing p-chlorobenzeneboronic acid; starting from ortho-nitroaniline, synthesizing o-nitro halogenated benzene, or directly synthesizing o-amino halogenated benzene; and under the action of specific catalysts, enabling p-chlorophenylboronic acid to perform a series of reactions such as coupling, reduction, amidation and the like with o-nitro halogenated benzene or o-amino halogenated benzene to prepare boscalid. The preparation method disclosed by the invention is simple to operate, high in yield, small in pollution, low in cost and high in purity, and is very suitable for industrial production.